Jan 22 2013
C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. C-RAD has received a first order of two Catalyst systems to the Chinese market.
The Catalyst™ is a next-generation high performance tracking system based on optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable clinicians to perform a real-time assessment of patient positioning errors before and during treatment delivery. Interfaces to major vendors ensure a completely integrated workflow.
C-RAD is in China selling both direct and via distributors to the radiation therapy clinics. The C-RAD sales office in Shanghai was founded in July 2012. Results of the improved presence on the market can already be seen. Technical support can locally be offered to distributors and end customers.
Erik Hedlund, CEO, C-RAD AB:
”We are happy to announce the first orders of the Catalyst system to the Chinese market. So far altogether 8 Sentinel and Catalyst systems have been ordered by Chinese customers. As soon as SFDA approval of the two systems will be in place, sales will increase. Approval of the Sentinel is expected to be in place spring 2013.”
Markus Braun, Sales manager, C-RAD WOFE:
“C-RAD and its subsidiary in China is further expanding the activities for Sentinel and Catalyst systems on the Chinese market. We have from our newly appointed distributor received two orders of the Catalyst system.
The Chinese market will continue to grow in 2013. The radiation therapy clinics are showing a positive attitude to the C-RAD products. C-RAD will conduct further measures in expanding the market presence generating more value by focused marketing and sales activities and further collaborations that will lay down the future success in the Chinese market.”